Management of type 2 diabetes in the obese patient: Current concerns and emerging therapies

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 401-417

  Krentz, Andrew J ^a,b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anti diabetic agents; Anti obesity agents; Obesity; Pathophysiology; Type 2 diabetes mellitus

Indexed keywords

ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLICLAZIDE; GLIMEPIRIDE PLUS PIOGLITAZONE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLIPIZIDE; GLIPIZIDE PLUS METFORMIN; GLITAZONE DERIVATIVE; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; SITAGLIPTIN; TETRAHYDROLIPSTATIN; TOLAZAMIDE; TOLBUTAMIDE; UNINDEXED DRUG; VILDAGLIPTIN;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANEMIA; BODY WEIGHT; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG ACTIVITY; DYSPEPSIA; EDEMA; FLATULENCE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HEADACHE; HEART FAILURE; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; LIVER TOXICITY; MEDLINE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 39749202259     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X219661     Document Type: Review

References (141)

1. Colditz GA, Willett WC, Rotnitzky A, et al. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6
2. Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol 1997;146:214-22
3. Resnick HE, Valsania P, Halter J, et al. Relation of weight gain and weight loss on subsequent diabetes risk in overweight adults. J Epidemiol Community Health 2000;54:596-602
4. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10 year period. Arch Intern Med 2001;161:1581-6
5. Weiss R, Caprio S. The metabolic consequences of childhood obesity. Best Pract Res Clin Endocrinol Metab 2005;19:405-19
6. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49:883-8
7. Yusuf S, Hawken S, Ounpuu S, et al.; for the INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9
8. Molavi B, Rasouli N, Kern PA. The prevention and treatment of metabolic syndrome and high-risk obesity. Curr Opin Cardiol 2006;21:479-85
9. LaMonte MJ, Blair SN. Physical activity, cardiorespiratory fitness, and adiposity: contributions to disease risk. Curr Opin Clin Nutr Metab Care 2006;9:540-6
10. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004;59:207-23
11. Lebovitz HE. Insulin resistance - a common link between type 2 diabetes and cardiovascular disease. Diabetes Obes Metab 2006;8:237-49
12. Scheen AJ. From obesity to diabetes: why, when and who? Acta Clin Belg 2000;55:9-15
13. Tuomilehto J, Lindstrom J, Eriksson JC, et al.; for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
14. Knowler WC, Barrett-Connor E, Fowler SE, et al.; for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
15. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care 2003;30:465-91
16. Manley SE, Stratton IM, Cull CA, et al.; for the United Kingdom Prospective Diabetes Study Group. Effect of three months' diet after diagnosis of type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). United Kingdom Prospective Diabetes Study Group. Diabet Med 2000;17:518-23
17. Adler A. Obesity and target organ damage: diabetes. Int J Obes Relat Metab Disord 2002;26(Suppl 4):S11-4
18. Klein S, Burke LE, Bray GA, et al.; for the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004;110:2952-67
19. Lean M, Finer N. ABC of obesity. Management: part II - drugs. BMJ 2006;333:794-7
20. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411
21. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
22. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006;29:435-49
23. Mooradian AD. Obesity: a rational target for managing diabetes mellitus. Growth Hormone IGF Res 2001;11(Suppl A):S79-83
24. Krentz AJ, Singh BM, Hale PJ, et al. Basal intermediary metabolism in impaired glucose tolerance and morbid obesity. Diabetes Res 1992;20:51-60
25. Ferrannini E, Barrett EJ, Bevilacqua S, et al. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72:1737-47
26. Roden M, Price TB, Perseghin G, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996;97:2859-65
27. Mason TM, Goh T, Tchipashvili V, et al. Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. Diabetes 1999;48:524-30
28. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999;42:128-38
29. Evans AJ, Krentz AJ. Insulin resistance and beta-cell dysfunction as therapeutic targets in type 2 diabetes. Diabetes Obes Metab 2001;3:219-29
30. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702-6
31. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8
32. Morris RD, Rimm DL, Hartz AJ, et al. Obesity and heredity in the etiology of non-insulin-dependent diabetes mellitus in 32662 adult white women. Am J Epidemiol 1989;130:112-21
33. Bray GA. Obesity increases risk for diabetes. Int J Obes Relat Metab Disord 1992;16(Suppl 4):S13-7
34. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000;160:898-904
35. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990;132:501-13
36. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
37. Diabetes. Diabetes Fact Sheet No. 312. Basel, Switzerland. World Health Organization: September 2006. Available from http://www.who.int/mediacentre/ factsheets/fs312/en/ [Last accessed 9 Feb 2007]
38. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282:1519-22
39. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-9
40. Obesity and overweight. Global Strategy on Diet, Physical Activity and Health. Basel, Switzerland. World Health Organization: 2007. Available from http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/ [Last accessed 9 Feb 2007]
41. Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism 2006;55(Suppl 1):S16-9
42. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53
43. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006;55(Suppl 1):S20-7
44. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 1972;21:976-9
45. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
46. Prandin [package insert]. Princeton, NJ, USA. Novo Nordisk A/S, 2006
47. Starlix [package insert]. East Hartford, NJ, USA. Novartis Pharmaceuticals USA, 2006
48. Mayerson AB, Inzucchi SE. Type 2 diabetes therapy. A pathophysiologically based approach. Postgrad Med 2002;111:83-4,87-92,95. Erratum in Postgrad Med 2002;111:24
49. Marbury T, Huang WC, Strange P, et al. Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res Clin Pract 1999;43:155-66
50. Rosenstock J, Hassman DR. Madder RD, et al.; for the Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy. Diabetes Care 2004;27:1265-70
51. Inzucchi S. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287:360-72
52. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
53. Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2000;108:151-63
54. Kimmel B, Inzucchi S. Oral agents for type 2 diabetes: an update. Clin Diabetes 2005;23:64-76
55. Dormandy JA, Charbonnel B, Eckland DJ, et al.; for the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89
56. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-2
57. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
58. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357:844-6
59. Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007;16:1065-71
60. Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
61. Purnell JQ, Weyer C. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity. Treat Endocrinol 2003;2:33-47
62. Isley WL. Glitazones, glycemia, and global health status. Diabetes Care 2001;24:2158-9
63. Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006;29:510-4
64. Malone M. Medications associated with weight gain. Ann Pharmacother 2005;39:2046-55
65. Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-6
66. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108:2941-8
67. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-307
68. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002;137:25-33
69. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9
70. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7
71. Hoffman J, Spengler M. Efficacy of 24 week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II study. Am J Med 1997;103:483-90
72. Libby P. Metformin and vascular protection: a cardiologist's view. Diabetes Metab 2003;29:6S117-20
73. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65. Erratum in Lancet 1998;352:1558
74. Robinson AC, Burke J, Robinson S, et al. The effects of met-formin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998;21:701-5
75. Aviles-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;131:182-8
76. Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia 1999;42:406-12
77. Chiasson JL, Josse RG, Gomis R, et al.; for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7
78. Chiasson JL, Josse RG, Gomis R, et al.; for the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94
79. Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993;16:21-31
80. Landstedt-Hallin L, Adamson U, Arner P, et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995;18:1183-6
81. Chow CC, Tsang LW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995;18:307-14
82. Riddle MC, Schneider J; for the Glimepiride Combination Group. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. The Glimepiride Combination Group. Diabetes Care 1998;21:1052-7
83. Gough SC. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77:1-15 [Epub ahead of print 16 Nov 2006]
84. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004;89:2595-600
85. Kelley DE, Wing R, Buonocore C, et al. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993;77:1287-93
86. UK Prospective Diabetes Study (UKPDS) Group. United Kingdom prospective diabetes study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8
87. Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749-53
88. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992; 55:309S-13
89. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity. Int J Obes Relat Metab Disord 2003;27:1437-46
90. Torgerson JS, Hauptman J, Boldrin MN, et al. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155-61
91. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes Relat Metab Disord 1997;21:S30-6
92. Luque CA, Rey JA. Sibutramine: a serotonin reuptake-inhibitor for the treatment of obesity. Ann Pharmacother 1999;33:968-78
93. Vettor R, Serra R, Fabris R, et al. Effect of sibutramine on weight management and metabolic control in type 2 diabetes. A meta-analysis of clinical studies. Diabetes Care 2005;28:942-9
94. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
95. Genuth S. Implications of the United Kingdom Prospective Diabetes Study for patients with obesity and type 2 diabetes. Obes Res 2000;8:198-201
96. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003;32:805-22, viii
97. Gilden Tsai A, Wadden TA. The evolution of very-low-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006;14:1283-93
98. Fetner R, McGinty J, Russell C, et al. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis 2005;1:589-97
99. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61
100. Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase 4 with antidiabetic properties. Expert Opin Investig Drugs 2006;15:431-42
101. Barnett A. DPP 4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006;60:1454-70
102. Duttaroy A, Voelker F, Merriam K, et al. The DPP 4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases apoptosis. Program and abstracts of the 65th scientific sessions of the American Diabetes Association. June 10-14, 2005; San Diego, CA, USA [abstract 572-P]
103. Kahn SE, Haffner SM, Heise MA, et al.; for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
104. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med 2006;355:2477-80
105. Buse JB, Henry RR, Han J, et al.; for the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin 4) on glycemic control and weight over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
106. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin 4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
107. Kendall DM, Riddle MS, Rosenstock J, et al. Effects of exenatide (exendin 4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
108. Ratner RE, Maggs D, Nielsen LL, et al. Long term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006;4:419-28
109. Heine RJ, Van Gaal LF, Johns D, et al.; for the GWAA Study Group. Exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
110. Byetta [package insert]. San Diego, CA, USA. Amylin Pharmaceuticals, Inc., 2006
111. Vilsbøll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia episodes in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10
112. Aschner P, Kipnes M, Lunceford J, et al. Effect of the dipeptidyl peptidase 4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-7
113. Dejager S, Razac S, Foley JE, et al. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24 week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res 2007;39:218-23
114. Dejager S, Lebeaut A, Couturier A, et al. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A29 [abstract 120 OR]
115. Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-5 [Epub ahead of print 2 Feb 2007 doi:10.2337/dc06-1732]
116. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase 4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
117. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24 week, double-blind, randomized trial. Diabetes Care 2007;30:217-23
118. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase 4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clinical Therapeutics 2006;28:1556-68
119. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase 4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-71
120. Ahrén B, Pacini G, Foley J, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40
121. Mari A, Sallas M, He YL, et al. Vildagliptin, a dipeptidyl peptidase IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888-94
122. Stein P. Sitagliptin: a novel dipeptidyl peptidase-4 inhibitor for the treatment of patients with type 2 diabetes. Presented at: American Diabetes Association 66th Scientific Sessions; June 9-13, 2006; Washington, DC
123. Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus. Presented at: American Diabetes Association 66th Scientific Sessions; June 9-13, 2006; Washington, DC
124. Januvia [package insert]. Whitehouse Station, NJ, USA. Merck & Co., Inc., 2006
125. Fonseca V, Dejager S, Albrecht D, et al. Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM). Diabetes 2006;55(Suppl 1):A111 [abstract 467-P]
126. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004;3:771-84
127. Bramlage P, Muhlen I, Randeva H, et al. Cardiovascular risk management by blocking the endocannabinoid system. Exp Clin Endocrinol Diabetes 2006;114:75-81
128. Després JP, Golay A, Sjöström L; for the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-34
129. Van Gaal LF, Rissanen AM, Scheen AJ, et al.; for the RIO-Europe Study Group. Effects of the cannabinoid 1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1 year experience from the RIO-Europe Study. Lancet 2005;365:1389-97. Erratum in Lancet 2005;366:370
130. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.; for the RIO-North America Study Group. Effect of rimonabant, a cannabinoid 1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75
131. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 2006;368:1660-72. Erratum in JAMA 2006;295:1252
132. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-80
133. Wing RR, Marcus MD, Epstein LH, et al. Type II diabetic subjects lose less weight than their overweight nondiabetic spouses. Diabetes Care 1987;10:563-6
134. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
135. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2002;110:2952-67
136. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-13
137. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005;48:838-48
138. Symlin [package insert]. San Diego, CA, USA. Amylin Pharmaceuticals, Inc., 2005
139. Maggs D, Shen L, Brown D, et al. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis. Metabolism 2003;12:1638-42
140. Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 2003;5:408-14
141. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004;12:661-68